Lead Product(s) : Dapagliflozin,Gemigliptin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LG Chem Sets Sights on Global Market with Launch of Diabetes Combination Therapy Zemidapa
Details : Zemidapa is a fixed-dose combination therapy that brings together two active ingredients: Zemiglo, Korea’s first domestically developed DPP-4 inhibitor, and dapagliflozin, an SGLT-2 inhibitor.
Product Name : Zemidapa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2025
Lead Product(s) : Dapagliflozin,Gemigliptin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enavogliflozin,Gemigliptin,Metformin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Enavogliflozin is an SGLT-2 inhibitor for diabetes in development by Daewoong for the first time in South Korea. The safety of Enavogliflozin has been proven through three sequential clinical trials of monotherapy, metformin combination, and Metformin-Ge...
Product Name : DWP16001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 25, 2022
Lead Product(s) : Enavogliflozin,Gemigliptin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enavogliflozin,Gemigliptin,Metformin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DWP16001 (enavogliflozin) is a new diabetes drug in the SGLT-2 inhibitor class. The two combination trials, Enavogliflozin-Metformin and Enavogliflozin-Metformin-Gemigliptin combination, demonstrated non-inferiority in HbAc1 change compared to dapagliflo...
Product Name : DWP16001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2022
Lead Product(s) : Enavogliflozin,Gemigliptin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable